The N54 mutant of Gαs has a conditional dominant negative phenotype which suppresses hormone-stimulated but not basal cAMP levels  by Cleator, John H et al.
The N54 mutant of GKs has a conditional dominant
negative phenotype which suppresses hormone-stimulated but not basal
cAMP levels
John H. Cleator, Nitin D. Mehta, David T. Kurtz, John D. Hildebrandt*
Medical University of South Carolina, Department of Cell and Molecular Pharmacology, Charleston, SC 29425, USA
Received 9 November 1998; received in revised form 8 December 1998
Abstract The phenotype of a Ser to Asn mutation at position 54
of the K subunit of Gs (N54-Ks) was characterized in transient
transfection experiments in COS and HEK293 cells. Expression
of either wild type or N54-Ks increased basal cAMP levels. In
contrast, expression of wild type Ks potentiated agonist-
stimulated cAMP levels, while expression of N54-Ks caused a
decrease. Thus, the N54-Ks mutant possesses a conditional
dominant negative phenotype, suppressing preferentially hor-
mone-stimulated effects.
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1. Introduction
Heterotrimeric GTP binding proteins, or G proteins, trans-
duce signals from receptors on the surface of the cell to var-
ious intracellular e¡ector enzymes. The superfamily of GTP
binding proteins, which includes among others the K subunits
of heterotrimeric G proteins and the monomeric GTP binding
proteins, share four conserved amino acid sequences that form
the core of the GTP regulatory mechanism of these proteins
[1^3]. The consensus sequence of the ¢rst conserved region of
the guanine nucleotide binding site is GX4GK(S/T), which
includes Ser-17 in Ras and the equivalent Ser-54 of GKs.
These residues are involved in binding Mg2 ion when it is
complexed with nucleotide [4]. Ras with a Ser to Asn muta-
tion at this site (S17N) has an increased preference for GDP
over GTP, and a dominant negative phenotype [5].
Previously, the Ser to Asn mutation at position 54 of Ks
(N54-Ks) was characterized in S49 cyc3 cells (which lack en-
dogenous Ks) by measuring adenylyl cyclase activity in broken
cell preparations [6]. Those studies suggest that it has an in-
creased preference for GDP, especially in the presence of hor-
mone stimulation, similar to the altered nucleotide binding of
the N17-Ras protein [5]. Those studies did not establish, how-
ever, the phenotype of the N54 mutant in intact cells. To
determine the phenotype of N54-Ks when expressed in intact
cells with endogenous Ks present, COS cells and HEK293 cells
were transiently transfected with either wild type or mutant
Ks. These studies show that the N54-Ks mutant has a condi-
tional dominant negative phenotype expressed preferentially
in the presence of receptor activation of the protein.
2. Materials and methods
2.1. Materials
[3H]Adenine, donkey anti-rabbit horseradish peroxidase (HRP)
linked antibody, and ECL reagents were purchased from Amersham.
Bovine thyroid stimulating hormone (TSH, lot AFP-5555B) was ob-
tained from the National Hormone and Pituitary Program, NIDDK,
and Dr. A.F. Parlow. All other materials were of the highest quality
grade available.
2.2. Construction of vectors
cDNAs encoding the long form of GKs and the N54 mutation
of GKs in pMV7 [6] were subcloned into the HindIII site of the
mammalian expression vector pcDNA3 (Invitrogen) driven by the
CMV promoter. The activated Ks mutant (Q212L) in the mammalian
expression vector pCr/CMV was kindly provided by Dr. R. Iyengar.
The rat TSH receptor (TSH-R) cDNA inserted in the SV40 promoter-
driven expression vector pSG5 [7] was kindly provided by Dr. L.
Kohn.
2.3. Transient transfections
COS-1 and HEK293 cells were grown in DMEM containing 10%
FBS at 37‡C and were transfected with lipofectamine (Gibco). cDNAs
were mixed with lipofectamine in OPTI-MEM and added to either
COS cells or HEK293 cells in 6 well dishes (1U105 or 4U105, respec-
tively) and allowed to incubate for 5 h. Total cDNA was kept con-
stant by addition of vector, pcDNA3. Transfections were stopped by
the addition of 20% FBS in DMEM. The next day, cells were replated
into 24 well plates for cAMP determinations or 12 well plates to
provide samples for Western blots. Cells were used in an experiment
24 h later.
2.4. cAMP determination
cAMP was measured by use of the [3H]adenine uptake assay [8].
Cells were labelled with 1 WCi/ml [3H]adenine in 0.5 ml DMEM/10%
serum for approximately 24 h prior to treatment with hormone. Cells
were washed once with DMEM/20 mM Na-HEPES, followed by in-
cubation in DMEM/20 mM Na-HEPES containing 500 WM IBMX
for 10 min prior to hormone treatment. Cells were stimulated with
indicated hormone (3 nM TSH or 10 WM isoproterenol) for 20 min at
32‡C. Stimulation was terminated by the addition of 5% TCA solu-
tion containing 1 mM ATP and 1mM cAMP. [3H]cAMP was sepa-
rated from 3H-labelled adenine nucleotides, principally [3H]ATP, by
sequential chromatography on Dowex and alumina columns. Both
[3H]cAMP and 3H-labelled adenine nucleotides were recovered from
the columns and data are expressed as the percent of total 3H recov-
ered as [3H]cAMP. Values represent mean of triplicate data points þ
S.E.M. Figures shown are representative of experiments conducted at
least three times.
2.5. Immunoblotting
Samples were prepared by washing cells in PBS followed by addi-
tion of sample bu¡er containing 10% L-mercaptoethanol. Proteins
were separated by SDS polyacrylamide gel electrophoresis according
to Laemmli [9] and transferred [10] to nitrocellulose using a Bio-Rad
semi-dry transfer apparatus. Proteins were incubated with anti-Ks
antibody (ASC) produced according to the protocol of Spiegel [11]
or with a common anti-L antibody (BC1) [12]. Bands were visualized
by ECL after incubation with goat anti-rabbit HRP conjugate (New
England Nuclear).
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3. Results
3.1. E¡ect of wild type Ks or N54-Ks on cAMP levels in COS-1
and HEK293 cells
Transient transfection of COS-1 or HEK 293 cells with
increasing amounts of either wild type Ks or N54-Ks cDNA
resulted in comparable increases in Ks immunoreactivity with
little or no change in GL subunit levels (Fig. 1A,D, respec-
tively). This increased expression of Ks protein was associated
with increased basal cAMP accumulation, and the mutant was
slightly more e¡ective than wild type Ks (Fig. 1B,E, respec-
tively). In contrast, cellular cAMP levels were less a¡ected by
isoproterenol in the presence of the mutant than wild type Ks
(Fig. 1B,E). Consequently, agonist-stimulated cAMP levels
were slightly but consistently less in both cell lines transfected
with the mutant than in cells transfected with wild type Ks
(Fig. 1C,F).
These experiments suggested that N54-Ks selectively de-
creases agonist-stimulated cAMP levels while at the same
time increasing basal cAMP. The ability to substantiate these
conclusions seemed limited, however, in transient transfection
assays using the endogenous L-adrenergic receptors of the
transfected cell lines. The degree of e¡ect of GKs expression
on agonist-stimulated cAMP levels appeared to be explained
by the percentage of the cells that were transfected, as deter-
mined by immuno£uorescence studies with green £uorescence
protein (data not shown). To circumvent these problems, Ks
was co-expressed in cells with exogenous receptors not nor-
mally found in these cells.
3.2. E¡ect of wild type Ks or N54-Ks on stimulation of cAMP
levels through expressed receptors coupled to Gs
To study the interaction of Ks proteins with an exogenously
expressed receptor, HEK293 cells were transfected with the
rat TSH receptor (TSH-R) [7]. Basal and agonist-stimulated
cAMP levels in HEK293 cells transfected with a ¢xed amount
of TSH-R cDNA and increasing amounts of either wild type
or mutant cDNA showed the same pattern of responses (Fig.
2) seen previously with the endogenous L-adrenergic receptor
(Fig. 1). The mutant caused a slightly greater increase in basal
cAMP levels than did wild type Ks, whereas the reverse was
true for TSH-stimulated levels (Fig. 2A), and the di¡erence in
TSH-stimulated and basal activities increased for wild type Ks
but decreased for the mutant (Fig. 2B). These same patterns
were also seen when the TSH-R response was characterized in
COS-1 cells (Fig. 2C,D).
3.3. N54-Ks has inherent basal activity but less than that of a
constitutively activated mutant
There seemed to be two components to the phenotype of
the N54-Ks mutant when expressed in intact cells. The ¢rst
was a decreased ability of receptors to stimulate cAMP levels
in response to agonists. The second was an increased basal
level of cAMP production. The increased basal activity of the
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Fig. 1. A: E¡ect of expression of wild type Ks or N54-Ks in COS-1 cells on Ks and L immunoreactivity. B: Expression of wild type Ks or N54-
Ks in COS-1 cells and their e¡ects on basal and isoproterenol-stimulated cAMP levels. C: E¡ect of wild type or N54-Ks on isoproterenol-stimu-
lated cAMP levels in COS-1 cells. The graph was generated by subtracting basal levels from isoproterenol-stimulated cAMP levels from B. D:
E¡ect of expression of wild type Ks or N54-Ks in COS-1 cells on Ks and L immunoreactivity. E: Expression of wild type Ks or N54-Ks in
HEK293 cells and their e¡ects on basal and isoproterenol-stimulated cAMP levels. F: E¡ect of wild type or N54-Ks on isoproterenol-stimulated
cAMP levels in HEK293 cells. The graph was generated by subtracting basal levels from isoproterenol-stimulated cAMP levels from E.
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mutant might be explained by its increased nucleotide ex-
change rate for both GDP and GTP [6]. It was not clear,
however, whether this activity was comparable to that of
wild type Ks, or greater than that of the wild type protein
and closer to that of a constitutively-active mutant. To deter-
mine the inherent activity of N54-Ks compared to that of an
activated Ks* (Q212L-Ks designated Ks*), cAMP production
was determined in COS-1 cells (Fig. 3A,B) and HEK293 cells
(Fig. 3C,D) at approximately equal levels of protein expres-
sion for wild type, N54 and activated (Ks*) Ks.
Expression of comparable amounts of immunoreactive pro-
tein required about 10 times the amount of Ks* cDNA
(450 ng) compared to either N54 or wild type cDNA (45ng)
(Fig. 3A,C). This may be due to greater instability of the
activated protein, although we have not attempted to verify
this hypothesis. One di¡erence in the two cell lines was that
transfection of Ks*, which is the short form of the protein, in
COS-1 cells resulted in an increase in the endogenous expres-
sion of the long form of Ks (Fig. 3A). In contrast, in HEK293
cells, expression of Ks* did not cause this unexplained in-
crease/induction (Fig. 3C). Regardless, in both cell types
and at equal levels of protein expression, cAMP levels in
the presence of activated Ks* are approximately 10 times high-
er than those for either N54 or wild type Ks (Fig. 3B,D).
These experiments indicate that even though basal activity is
increased for N54-Ks, it does not have the same phenotype as
an activating mutation.
4. Discussion
When expressed in COS and HEK293 cells the N54-Ks mu-
tant has two observable phenotypes which might seem contra-
dictory without the previous biochemical characterization of
the mutant [6]. First, in the absence of hormone, the mutant
activates adenylyl cyclase in a hormone-independent manner.
This activity is slightly greater than that of wild type Ks,
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Fig. 2. A: Expression of wild type Ks or N54-Ks in HEK293 cells
co-expressing TSH-R and their e¡ects on TSH stimulation of
cAMP levels. Cells were transfected with 0.8 Wg TSH-R cDNA
along with indicated amounts of either wild type or N54-Ks cDNA.
B: E¡ect of wild type or N54-Ks on TSH-stimulated cAMP levels in
HEK293 cells. The graph was generated by subtracting basal levels
from TSH cAMP levels from A. C: E¡ect of co-expression of
TSH-R with either wild type Ks or N54-Ks in COS-1 cells on basal
and TSH-stimulated cAMP levels. Cells were transfected with 0.4 Wg
TSH-R cDNA along with indicated amounts of either wild type or
N54-Ks cDNA. D: E¡ect of wild type Ks or N54-Ks on TSH-stimu-
lated cAMP levels in COS-1 cells. The graph was generated by sub-
tracting basal levels from TSH cAMP levels from C.
Fig. 3. The relationship between the inherent activity of wild type, N54-Ks, and Ks* when expressed at comparable levels in cells. A: Immuno-
reactivity of Ks proteins expressed in COS-1 cells. For both A and B, COS-1 cells were transfected with either 450 ng pcDNA3, 45 ng wild
type Ks, 45 ng N54-Ks, or 450 ng Ks* cDNA. B: E¡ect of expression of Ks proteins on basal cAMP levels in COS-1 cells. C: E¡ect of expres-
sion of Ks proteins on immunoreactivity of Ks in HEK293 cells. For both C and D, HEK293 cells were transfected with either 1 Wg pcDNA3,
100 ng wild type Ks, 100 ng N54-Ks, or 1 Wg Ks* cDNA. D: E¡ect of expression of Ks proteins on basal cAMP levels in HEK293 cells.
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particularly at higher levels of expression, but signi¢cantly less
than that of strongly activating Ks mutations such as Q212L.
This property is explainable by the increased nucleotide ex-
change rate of the mutant compared to wild type Ks and by
the fact that the mutant can stimulate adenylyl cyclase [6].
The second observable phenotype of the mutant is its abil-
ity to interfere with receptor-stimulated cAMP levels even
when the receptor uses endogenous Ks protein. This is seen
most clearly for the TSH receptor expressed in HEK293 cells
(Fig. 2A,B), but this phenotype is consistently observed with
three di¡erent Ks-coupled receptors (L-adrenergic, TSH, VIP)
(VIP-R data not shown) in three di¡erent cell lines (COS-1
and HEK293). In all of these cases the di¡erence between
agonist-stimulated and basal cAMP decreased in the presence
of N54-Ks, but increased with expression of wild type Ks. The
less than additive e¡ect of basal and receptor-stimulated
cAMP levels in cells expressing N54-Ks, could result from
cAMP production being rate limiting (i.e. the cells could
only produce so much cAMP, so that increased basal cAMP
would decrease the amount of cAMP that could be stimulated
by hormone). That this is not the case is indicated by the fact
that greater e¡ects on cAMP levels could be obtained by
receptor activation in cells expressing wild type Ks. Instead,
these results most likely indicate that N54-Ks interferes with
receptor stimulation of cAMP levels even though it does not
suppress basal cAMP levels. Thus, the N54-Ks mutant has a
conditional dominant negative phenotype that speci¢cally in-
terferes with hormone stimulation of cAMP levels in cells.
This e¡ect is presumably related to the observation that re-
ceptor stimulation increases the preference of the mutant for
GDP [6].
Whether the dominant negative e¡ect of N54 Ks is upstream
on receptor or downstream on adenylyl cyclase remains to be
established. The mechanism of N17 ras is not completely clear
either, with evidence for both upstream [13,14] and down-
stream [13] e¡ects of that mutant. A clue to the mechanism
of the mutant may be its high concentrations required relative
to endogenous Ks and the fact that it only incompletely sup-
presses TSH stimulation. However, an additional factor for
N54 Ks is LQ, which could modify either upstream or down-
stream e¡ects of the mutant. Future studies will examine the
mechanism of action of the mutant and the e¡ect of LQ on its
phenotype.
Bacterial toxins and mutations of K subunits that alter their
GTPase activity can produce disease, underscoring the impor-
tance of the binding and hydrolysis of guanine nucleotide to
G protein function. Both loss and gain of function mutations
in Ks have been implicated in human disease [15]. Somatic
mutation of either Arg-201 or Glu-227 results in loss of the
GTPase activity of Ks, associated with hyperfunction and un-
controlled growth of thyroid and pituitary cells [15,16]. In
contrast, in pseudohypoparathyroidism, loss of function Ks
mutations result in resistance to hormones that stimulate G
protein-coupled receptors that activate Gs [15,17,18]. The par-
adoxical activity of the N54-Ks conditional dominant negative
mutant described here may de¢ne a new, potentially impor-
tant pathological phenotype, one neither analogous to consti-
tutively active nor to totally dysfunctional protein. Although
cells expressing this mutant would have a blunted response to
hormones, even if wild type Ks was also present, these cells
would still exhibit normal or even elevated basal cAMP levels
that could partly compensate for the lack of regulated levels.
Future studies will need to de¢ne whether such mutations
actually occur and if they cause speci¢c disease processes.
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